April 4, 2022, Tokyo, Japan — PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jiro Sugimoto) has successfully developed a novel TrkB agonist peptide which has the equivalent functions to recombinant Brain Derived Neurotropic Factor (BDNF). We will be marketing this product (BDNF alternative) from the beginning of April, 2022.
Development of Synthetic Peptide Growth Factors by PeptiGrowth
Conventional growth factors and cytokines used in the manufacturing of regenerative medicine and cell therapy products are facing various challenges such as lot-to-lot quality variations, potential contamination with biological impurities, low stability, and high cost. PeptiGrowth has been working on the development of a series of synthetic peptides that have the same functions as conventional growth factors and cytokines, and that can address and solve all these challenges. Its peptides are completely chemically synthesized and animal component-free.
About TrkB agonist peptide (BDNF alternative) [Product code: PG-003]
- Signal activation equivalent to recombinant BDNF
We performed a functional comparison test between our TrkB agonist peptide and commercially available recombinant BDNF. From the results, TrkB agonist peptide showed the activity to promote phosphorylation of TrkB receptor and expression of NFAT-responsive reporter gene at the same level per molecule as recombinant BDNF. The molecular weight of TrkB agonist peptide is approximately 5.1 kDa, which is approximately 2.5 times smaller than that of recombinant BDNF. Our TrkB agonist peptide is expected to be used as a neurotropic factor to grow, induce, and maintain neurons derived from neural progenitors. The product can be applied to several protocols in nerve regenerative medicine and cell therapy products recently developed for several types of neurons.
- Product name: *TrkB agonist peptide (BDNF alternative)
- Product Code: PG-003
- Product form: Lyophilized
- Storage conditions: -20 °C or less
- Purity: ≥95% by HPLC
- Molecular weight: 5,151.66
- Packaging Size: *10 μg (volume per glass vial)
*This product can be provided as Animal Component Free (ACF).
*This product is for testing and research use only (RUO).
*There is a possibility that the specification will be changed.
To Purchase Our Product
If you would like to purchase our products, please contact the agent in North America, Mitsubishi International Food Ingredients, Inc., at FineChem@mitsubishiingredients.com or +1 (201) 681-1268.
We can also discuss the supply of GMP-grade products for bulk consumption.
Development of other peptides by PeptiGrowth
PeptiGrowth was established in April 2020 as a joint venture between Mitsubishi Corporation and PeptiDream Inc. with the mission to address various challenges that regenerative medicine and cell therapy industry is facing and to contribute to its growth. Following HGF Alternative Peptide, TGFβ1 inhibitor, and BDNF alternative peptide, PeptiGrowth is planning to launch the next product by the end of September 2022. Details will be updated on its website upon release.